SAR 252067Alternative Names: Anti-LIGHT; Anti-LIGHT antibody; Anti-LIGHT monoclonal antibody; MDGN-002; Research programme: anti-LIGHT monoclonal antibody - sanofi-aventis; SAR252067
Latest Information Update: 30 Dec 2016
At a glance
- Originator Kyowa Hakko Kirin; La Jolla Institute for Allergy & Immunology
- Developer Kyowa Hakko Kirin; Sanofi
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Crohn's disease; Ulcerative colitis